中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

经肝动脉化疗栓塞术治疗肝细胞癌的预后影响因素分析

马士杰 邹绍静 罗小玲 李倩君 黄家胜

马士杰, 邹绍静, 罗小玲, 李倩君, 黄家胜. 经肝动脉化疗栓塞术治疗肝细胞癌的预后影响因素分析[J]. 临床肝胆病杂志, 2016, 32(1): 80-83. DOI: 10.3969/j.issn.1001-5256.2016.01.013
引用本文: 马士杰, 邹绍静, 罗小玲, 李倩君, 黄家胜. 经肝动脉化疗栓塞术治疗肝细胞癌的预后影响因素分析[J]. 临床肝胆病杂志, 2016, 32(1): 80-83. DOI: 10.3969/j.issn.1001-5256.2016.01.013
Ma ShiJie, Zou ShaoJing, Luo XiaoLing, Li QianJun, Huang JiaSheng. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2016, 32(1): 80-83. DOI: 10.3969/j.issn.1001-5256.2016.01.013
Citation: Ma ShiJie, Zou ShaoJing, Luo XiaoLing, Li QianJun, Huang JiaSheng. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2016, 32(1): 80-83. DOI: 10.3969/j.issn.1001-5256.2016.01.013

经肝动脉化疗栓塞术治疗肝细胞癌的预后影响因素分析

DOI: 10.3969/j.issn.1001-5256.2016.01.013
详细信息
  • 中图分类号: R735.7

Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

  • 摘要:

    目的探讨中晚期肝细胞癌(HCC)患者行肝动脉化疗栓塞术(TACE)的预后影响因素。方法回顾性分析南京医科大学附属淮安第一医院2007年5月-2012年5月收治的124例行TACE治疗的中晚期HCC患者的临床资料。应用Kaplan-Meier法计算累积生存率,Log-rank法进行检验;各影响因素行单因素Cox分析,再用多因素Cox逐步回归分析。结果 124例患者均获得随访,随访时间为340个月,患者0.5、1、2、3年累积生存率分别为97.6%、74.2%、15.5%、4.1%,中位生存时间为482 d。单因素分析显示,术前血清甲胎蛋白(AFP)水平、肿瘤大小、有无门静脉癌栓、肿瘤临床分期是HCC患者TACE预后的影响因素(P值均<0.001);进一步多因素Cox逐步回归分析显示,肿瘤大小、肿瘤临床分期、术前血清AFP水平、门静脉癌栓是HCC患者TACE预后的独立危险因素(Wald值分别为7.428、7.699、15.235、5.803,P值均<0.05)。结论肿瘤大小、肿瘤临床分期、术前血清AFP水平、有无门静脉癌栓是HCC患者TACE预后的独立危险...

     

  • [1]LIM HS,JEONG YY,KANG HK,et al.Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation[J].AJR Am J Roentgenol,2006,187(4):w341-w349.
    [2]Chinese Expert Consensus Statement Chinese Society of Liver Cancer.Clinical diagnosis and staging criteria for primary liver cancer[J].Chin J Hepatol,2001,9(6):324.(in Chinese)中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志,2001,9(6):324.
    [3]YANG LT,WANG XB,ZHANG YL,et al.Risk factors and prognosis for patients with residual tumor after radiofrequency ablation of hepatocellular carcinoma[J].Chin J Oncol,2010,32(4):309-312.(in Chinese)杨立涛,王新保,张云利,等.肝细胞癌射频消融治疗后肿瘤残留的危险因素及预后分析[J].中华肿瘤杂志,2010,32(4):309-312.
    [4]YIN L,LI H,LI AJ,et al.Partial hepatectomy vs.transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria:a RCT[J].J Hepatol,2014,61(1):82-88.
    [5]ZHOU TY,SUN JH,ZHANG YL,et al.Application of transcatheter arterial chemoembolization combined with selective portal vein embolization in two-stage hepatectomy of hepatocellular carcinoma[J].Chin J Dig,2014,9(34):582-587.(in Chinese)周坦洋,孙军辉,张岳林,等.肝动脉化学疗法栓塞联合选择性门静脉栓塞在肝癌二期切除术中的应用[J].中华消化杂志,2014,9(34):582-587.
    [6]FACCIORUSSO A,LICINIO R,MUSCATIELLO N,et al.Transarterial chemoembolization:evidences from the literature and applications in hepatocellular carcinoma patients[J].World J Hepatol,2015,7(16):2009-2019.
    [7]CHENG X,SUN P,HU QG,et al.Transarterial(chemo)embolization for curative resection of hepatocellular carcinoma:a systematic review and meta-analyses[J].J Cancer Res Clin Oncol,2014,140(7):1159-1170.
    [8]UM SH,MULHALL C,ALISA A,et al.Alpha-fetoprotein impairs APC function and induces their apoptosis[J].J Immunol,2004,173(3):1772-1778.
    [9]BEHBOUDI S,ALISA A,BOSWELL S,et al.Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease[J].Br J Cancer,2010,102(4):748-753.
    [10]WANG Y,CHEN Y,GE N,et al.Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization[J].Ann Surg Oncol,2012,19(11):3540-3546.
    [11]LI P,WANG SS,LIU H,et al.Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma[J].World J Gastroenterol,2011,17(41):4563-4571.
    [12]CHANG ZF,WANG MQ,LIU FY,et al.Prognostic significance of serum gamma-glutamyl transferase before transcatheter arterial chemoembolization in patients with intermediate hepatocellular carcinoma[J].Natl Med J China,2014,94(9):667-669.(in Chinese)常中飞,王茂强,刘凤永,等.中期原发性肝癌患者术前血清γ-谷氨酰转肽酶水平判断TACE治疗预后的意义[J].中华医学杂志,2014,94(9):667-669.
    [13]KANG HY,CHANG ZF,CHEN WZ,et al.Prognostic significance of serum gamma-glutamyl transferase before transcatheter arterial chemoembolization in young patients with primary hepatocellular carcinoma[J].China Med Herald,2015,12(2):98-102.(in Chinese)康海燕,常中飞,陈文彰,等.青少年原发性肝癌患者术前血清γ-谷氨酰转肽酶水平在肝动脉化疗栓塞治疗中的预后意义[J].中国医药导报,2015,12(2):98-102.
    [14]XIAO J,LI G,LIN S,et al.Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization[J].Int J Clin Exp Pathol,2014,7(3):1114-1123.
    [15]YU L,LYU WF.Analysis on prognostic factors in transcatheter hepatic arterial chemoembolization in treatment for adivanced liver cancer[J].Chin J Interv Imaging Ther,2015,12(1):14-17.(in Chinese)余梁,吕维富.经肝动脉化疗栓塞术治疗中晚期肝癌的预后因素分析[J].中国介入影像与治疗学,2015,12(1):14-17.
    [16]LLOVET JM,BRU'C,BRUIX J.Prognosis of hepatocellular carcinoma:the BCLC staging classification[J].Semin Liver Dis,1999,19(3):329-338.
  • 加载中
计量
  • 文章访问数:  2248
  • HTML全文浏览量:  23
  • PDF下载量:  432
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-09-14
  • 刊出日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回